Podcast Episode
Most CRISPR proteins used in medicine today are simply too large to fit inside adeno-associated virus vectors, the tiny biological packages that serve as the leading delivery method for getting gene therapies to specific tissues. That size limitation has meant CRISPR treatments have largely been confined to editing cells outside the body, such as blood and bone marrow cells, before reintroducing them to the patient.
The researchers then engineered an enhanced variant dubbed Al3Cas12f RKK, which dramatically boosted gene-editing efficiency from under ten percent to over eighty percent across multiple targets in human cells. At one commonly edited genomic region, efficiency reached ninety percent.
This work arrives alongside broader momentum in the compact CRISPR space. Metagenomi Therapeutics is separately advancing compact gene-editing tools toward clinical trials for haemophilia A, with plans to begin first-in-human studies in twenty twenty-six. If compact enzymes like Al3Cas12f RKK perform well inside delivery vehicles, they could open treatment pathways for a wide range of diseases that currently lack viable gene therapy options.
Scientists Shrink CRISPR Small Enough to Deliver Gene Editing Inside the Body
April 13, 2026
0:00
4:01
Researchers at the University of Texas at Austin have engineered a miniaturised CRISPR enzyme called Al3Cas12f that is small enough to fit inside viral delivery vehicles used in gene therapy. The engineered variant boosted editing efficiency from under ten percent to over eighty percent in human cells, potentially unlocking in-body gene editing for diseases like cancer and ALS.
A Smaller Pair of Molecular Scissors
A team of researchers at the University of Texas at Austin has solved one of gene therapy's most stubborn engineering problems: making a CRISPR gene-editing tool small enough to deliver directly inside the human body. The findings, published in Nature Structural and Molecular Biology, were announced by the National Institutes of Health this week.Most CRISPR proteins used in medicine today are simply too large to fit inside adeno-associated virus vectors, the tiny biological packages that serve as the leading delivery method for getting gene therapies to specific tissues. That size limitation has meant CRISPR treatments have largely been confined to editing cells outside the body, such as blood and bone marrow cells, before reintroducing them to the patient.
The Breakthrough
Working with Metagenomi Therapeutics, the UT Austin team identified a naturally occurring enzyme called Al3Cas12f that is compact enough to be packaged into these viral vectors. Using advanced imaging and machine learning, they analysed the enzyme's structure and discovered it forms a remarkably stable complex compared to other enzymes of similar size.The researchers then engineered an enhanced variant dubbed Al3Cas12f RKK, which dramatically boosted gene-editing efficiency from under ten percent to over eighty percent across multiple targets in human cells. At one commonly edited genomic region, efficiency reached ninety percent.
What This Means for Patients
The team tested their enhanced enzyme in human cell lines, targeting genes associated with cancer, atherosclerosis, and amyotrophic lateral sclerosis. The next step is to package the enzyme into viral vectors and test its performance under conditions that more closely mirror clinical use.This work arrives alongside broader momentum in the compact CRISPR space. Metagenomi Therapeutics is separately advancing compact gene-editing tools toward clinical trials for haemophilia A, with plans to begin first-in-human studies in twenty twenty-six. If compact enzymes like Al3Cas12f RKK perform well inside delivery vehicles, they could open treatment pathways for a wide range of diseases that currently lack viable gene therapy options.
Published April 13, 2026 at 9:59pm
